First CTCL Patients Enrolled in Phase 2 Trial of Topical Treatment WP1220
News
The Phase 2 clinical trial assessing Moleculin Biotech‘s STAT3 inhibitor, WP1220, for the topical treatment of cutaneous T-cell lymphoma (CTCL) lesions has enrolled the ... Read more